Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
24,622
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
stocks
The sectors set to soar on government spending
stocks
Chart of the Week: How private companies are reshaping public markets
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,065.70 | 11.20 | -0.12% |
| CAC 40 | 7,964.77 | 109.46 | -1.36% |
| DAX 40 | 23,734.02 | 315.72 | -1.31% |
| Dow JONES (US) | 46,912.30 | 398.70 | -0.84% |
| FTSE 100 | 9,735.78 | 41.30 | -0.42% |
| HKSE | 26,283.52 | 202.38 | -0.76% |
| NASDAQ | 23,053.99 | 445.80 | -1.90% |
| Nikkei 225 | 49,888.48 | 995.20 | -1.96% |
| NZX 50 Index | 13,647.43 | 70.62 | 0.52% |
| S&P 500 | 6,720.32 | 75.97 | -1.12% |
| S&P/ASX 200 | 8,801.50 | 9.00 | -0.10% |
| SSE Composite Index | 4,000.06 | 7.70 | -0.19% |